Elite Pharmaceuticals, Inc. (ELTP) increased its board from four to six directors and elected Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq., effective October 28, 2026. The Board unanimously elected both directors.
Each will receive compensation in the same manner as the Board’s other non-management directors. Each will serve until the next annual meeting and until a successor is duly elected and qualified, unless the director dies, resigns or is removed earlier.
Elite Pharmaceuticals Inc. (ELTP) director Barry H. Dash purchased 100,000 shares of common stock at $0.2598 per share on October 9, 2026. The shares were held directly, and he reported 3,365,555 shares after the purchase. The form reports no Rule 10b5-1 plan.
ELITE PHARMACEUTICALS INC (ELTP) director Barry H Dash reported purchasing 30,000 shares of common stock on August 19, 2026, in a purchase described as an open market or private transaction at $0.287 per share.
After this buy, he directly owns 3,265,555 shares of ELTP common stock, and no Rule 10b5-1 plan is reported for this transaction.
Elite Pharmaceuticals, Inc. reported financial results for the first quarter of fiscal year 2027, ended June 30, 2026. Consolidated revenues were $32.4 million, a decrease of $7.9 million or about 19.5% from the same quarter of the prior fiscal year, which had been its largest quarterly revenue. Income from operations was $7.5 million, down $14.2 million or about 65%, primarily due to lower margins on sales of the company’s generic Vyvanse product line as competitive market adjustments weighed more heavily on this quarter.
The company stated that, despite the year-over-year decline, first-quarter results are in line with the three preceding quarters. Net income attributable to common shareholders was $5.9 million. Management will discuss the results and provide a business update on a conference call scheduled for August 14, 2026 at 11:30 AM EDT.
Elite Pharmaceuticals, Inc. reported for the quarter ended June 30, 2026 revenue of $32.4 million, down from $40.2 million a year earlier, as increased competition, including on its Lisdexamfetamine line, reduced average net pricing. Cost of manufacturing rose to $18.8 million, cutting gross margin to 42% from 68% and reducing income from operations to $7.5 million from $21.7 million.
Despite weaker operating results, the company posted net income of $5.9 million, compared with a $5.9 million loss in the prior-year quarter, helped by a much smaller impact from warrant fair-value adjustments and higher interest income. Operating cash flow was strong at $10.1 million, and cash and restricted cash increased to $39.4 million. The balance sheet shows total assets of $139.7 million, liabilities of $34.8 million, and shareholders’ equity of $104.8 million, with working capital of $84.0 million.
Elite continues to expand its generic portfolio, launching methadone tablets in April 2026 and a generic Requip XL (ropinirole extended-release) in July 2026, and it filed an anticoagulant ANDA and reported positive pivotal bioequivalence results for an anticonvulsant generic. A patent suit by Purdue Pharma relating to Elite’s generic OxyContin ANDA was dismissed by court order in June 2026. Revenue remains concentrated, with two customers representing 73% of sales.
Elite Pharmaceuticals, Inc. filed an amended current report to correct the previously stated conference-call deadlines from November to August. The company plans to release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on August 13, 2026. Management will then host a conference call on August 14, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update. Investors can join via domestic dial-in 1-800-346-7359 or international 1-973-528-0008 using conference number 98840, and are invited to submit general and financial questions by specified email deadlines prior to the call. An audio replay will be available online.
Elite Pharmaceuticals, Inc. reported that it will release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on August 13, 2026. Management will then host a live conference call on August 14, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update.
Investors can join the call via domestic dial-in 1-800-346-7359 or international dial-in 1-973-528-0008, using conference number 98840. Stockholders are invited to submit general and financial questions in advance to dianne@elitepharma.com by the deadlines provided in the notice.
Elite Pharmaceuticals, Inc. reported the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP) in the United States. The product is offered in 2 mg, 4 mg, 6 mg, 8 mg and 12 mg strengths and is marketed and sold under the Elite Laboratories, Inc. label.
Ropinirole is a non-ergoline dopamine agonist used to treat Parkinson’s disease. According to IQVIA, the branded product and its equivalents generated $10 million in total U.S. sales for the twelve months ending June 2026, providing an indication of the market size for this therapy class.
Elite Pharmaceuticals reported sharply improved results for the fiscal year ended March 31, 2026. Consolidated revenues reached $148.9 million, an increase of $64.8 million, or about 77%, over the prior year. Income from operations was $49.1 million, up $29.5 million, or roughly 151%.
The company attributed the stronger operating income mainly to a full-year contribution from its Lisdexamfetamine product, revenues from Oxycodone Acetaminophen tablets launched during the year, and Naltrexone and Phentermine tablets sold exclusively under the Elite label, along with broad growth across its product lines.
Management will discuss these year-end 2026 results and recent business developments on a conference call scheduled for June 30, 2026 at 11:30 AM EDT, with domestic and international dial-in numbers and an audio replay link provided.
Elite Pharmaceuticals, Inc. provides an overview of its business in generic and specialty oral drugs in its annual report for the year ended March 31, 2026. The company now operates as a single ANDA-based segment after pausing NDA development, and reported ANDA segment revenue of $148.9 million, up from $84.0 million in the prior year.
Elite highlights a broad portfolio of solid oral dose generics, including CNS stimulants, bariatric, cardiovascular, pain and other therapies, all manufactured at its cGMP and DEA-registered Northvale, New Jersey facility. Recent launches include Methotrexate Tablets, several opioid combination pain products, Lisdex Capsules for ADHD, Oxy APAP Tablets, and Methadone Tablets, many acquired via a June 2024 asset purchase from Nostrum Laboratories.
The company notes expiration of its long-running Precision Dose license in September 2025, termination of a Prasco non-exclusive license in March 2025, and first international shipments of amphetamine tablets under a Dexcel agreement in July 2025. Development of its SequestOx abuse-deterrent opioid candidate remains paused, and a related patent and Loxapine Capsules were impaired after reassessing expected cash flows. As of June 27, 2026, Elite had a public float valued at approximately $534 million and 1,077,196,442 common shares outstanding, supported by a workforce of 65 employees.